Page last updated: 2024-12-11

ethyl arachidonate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ethyl arachidonate : A long-chain fatty acid ethyl ester resulting from the formal condensation of the carboxy group of arachidonic acid with the hydroxy group of ethanol. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5367369
CHEBI ID84873
SCHEMBL ID24208
MeSH IDM0109266

Synonyms (33)

Synonym
unii-3nu6034aw3
3nu6034aw3 ,
5,8,11,14-eicosatetraenoic acid, ethyl ester
ethyl 5,8,11,14-eicosatetraenoate (all z)
ethyl arachidonate
5,8,11,14-eicosatetraenoic acid, ethyl ester, (all z)-
1808-26-0
ethyl arachidonate, >=98.5% (gc), liquid
arachidonic acid ethyl ester
arachidonic acid, ethyl ester
ethyl (5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoate
CHEBI:84873
SCHEMBL24208
ethyl arachidonate [inci]
(5z,8z,11z,14z)-5,8,11,14-eicosatetraenoic acid, ethyl ester
arachidonic ethyl ester
5,8,11,14-eicosatetraenoic acid, ethyl ester, (all-z)-
ethyl (5z,8z,11z,14z)-5,8,11,14-icosatetraenoate #
AC-33775
HMS3650O13
5,8,11,14-eicosatetraenoic acid, ethyl ester, (5z,8z,11z,14z)-
ethyl arachidonate,10%
J-011545
Q27158140
sr-01000946819
SR-01000946819-1
DTXSID301016455
ethyl 5(z),8(z),11(z),14(z)-eicosatetraenoate
AS-75579
BAA80826
(5z,8z,11z,14z)-ethylicosa-5,8,11,14-tetraenoate
AKOS040763745
BP-29840

Research Excerpts

Effects

ExcerptReferenceRelevance
"Ethyl arachidonate has been shown previously to be the principal metabolite of ethanol in the brains of intoxicated individuals and effects of this ester on VGSCs and CB1 receptors may contribute to the depressant effects of alcohol."( The cannabinoid receptor agonist CP-55,940 and ethyl arachidonate interfere with [(3)H]batrachotoxinin A 20 alpha-benzoate binding to sodium channels and inhibit sodium channel function.
Duan, Y; Jain, S; Liao, C; Nicholson, RA, 2008
)
1.32

Dosage Studied

ExcerptRelevanceReference
" 2"-O-GIV exhibited a dose-response effect but alpha-tocopherol did not."( Inhibitory effect of 2"-O-glycosyl isovitexin and alpha-tocopherol on genotoxic glyoxal formation in a lipid peroxidation system.
Hagiwara, H; Hagiwara, Y; Nishiyama, T; Shibamoto, T, 1994
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
human xenobiotic metaboliteAny human metabolite produced by metabolism of a xenobiotic compound in humans.
human blood serum metaboliteAny metabolite (endogenous or exogenous) found in human blood serum samples.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
long-chain fatty acid ethyl esterA fatty acid ethyl ester resulting from the formal condensation of the carboxy group of a long-chain fatty acid with the hydroxy group of ethanol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (23.53)18.7374
1990's4 (23.53)18.2507
2000's8 (47.06)29.6817
2010's1 (5.88)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.19

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.19 (24.57)
Research Supply Index2.89 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.19)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]